{
    "info": {
        "nct_id": "NCT05609994",
        "official_title": "ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas",
        "inclusion_criteria": "1. Age ≥ 18 years\n2. IDH1R132H expression in primary tumor\n3. Clinical and/or radiographic, progressive Grade 2-3 glioma with greater than 2 cm of non-enhancing disease in one plane.\n4. 1st recurrence only\n5. Signed informed consent\n6. For females of child-bearing potential, negative serum pregnancy test at screening\n7. Women of childbearing potential and male participants must agree to practice contraception\n8. Karnofsky Performance Status (KPS) of ≥ 70\n9. Expected survival of ≥ 12 months\n10. Recovered from any clinically relevant toxicities associated with any prior surgery for the treatment of glioma unless stabilized under medical management\n11. Complete Blood Count (CBC)/differential with adequate bone marrow function as defined below within 2 weeks of enrollment:\n\n    1. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3\n    2. Platelet count ≥ 100,000 cells/mm3\n    3. Hemoglobin (Hgb) ≥ 10 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)\n12. Adequate renal function as defined below within 2 weeks of enrollment:\n\n    1. Blood urea nitrogen (BUN) ≤ 25 mg/dl\n    2. Creatinine ≤ 1.7 mg/dl\n13. Adequate hepatic function as defined below within 2 weeks of enrollment:\n\n    1. Bilirubin ≤ 2.0 mg/dl\n    2. Alanine transaminase (ALT) ≤ 3 x normal range\n    3. Aspartate aminotransferase (AST) ≤ 3 x normal range\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years (e.g., carcinoma in situ of the breast, oral cavity, and cervix are all permissible)\n2. Metastases detected below the tentorium or beyond the cranial vault\n3. More than 1 cm X 1 cm of enhancing disease on gadolinium contrasted MRI imaging\n4. Severe, active co-morbidity, defined as follows:\n\n   1. Unstable angina and/or congestive heart failure requiring hospitalization\n   2. Myocardial infarction within the last 6 months.\n   3. Known Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition (Note: human immunodeficiency virus [HIV] testing is not required for entry into this protocol. The need to exclude patients with Acquired Immunodeficiency Syndrome (AIDS) from this protocol is necessary because treatments involved in this protocol may be significantly immunosuppressive.)\n   4. Major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.\n5. Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug\n6. Patients with a heart-rate corrected QT interval using Fridericia's formula (QTcF) ≥ 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome)\n7. Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Subjects with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted (Note: Patients with chronic HBV that is adequately suppressed by institutional practice will be permitted.)\n8. Patients with active gastrointestinal disease, chronic diarrhea, previous gastric resection or lap band dysphagia, short-gut syndrome, gastroparesis, or other condition that limits the ingestion or gastrointestinal absorption of drugs administered orally (Note: Gastroesophageal reflux disease under medical treatment is allowed.)\n9. Patient taking any medications that are CYP3A or CYP2C9 substrates with a narrow therapeutic index (Note: Patients should be transferred to other medications before receiving the first dose of study drug.)\n10. Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study\n11. Patients with known hypersensitivity to GM-CSF, yeast-derived products, or any component of Leukine®\n12. Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine.\n13. Known hypersensitivity to any component of vorasidenib\n14. Prior therapy with mIDH1 targeted therapeutics\n15. Unable to undergo MRI imaging",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. IDH1R132H expression in primary tumor",
            "criterions": [
                {
                    "exact_snippets": "IDH1R132H expression in primary tumor",
                    "criterion": "IDH1R132H expression in primary tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1000 cells/mm3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cells/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Women of childbearing potential and male participants must agree to practice contraception",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential ... must agree to practice contraception",
                    "criterion": "contraception agreement (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to practice contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "male participants must agree to practice contraception",
                    "criterion": "contraception agreement (male participants)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to practice contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Bilirubin ≤ 2.0 mg/dl",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤ 2.0 mg/dl",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Creatinine ≤ 1.7 mg/dl",
            "criterions": [
                {
                    "exact_snippets": "Creatinine ≤ 1.7 mg/dl",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.7,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Adequate hepatic function as defined below within 2 weeks of enrollment:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Adequate renal function as defined below within 2 weeks of enrollment:",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Recovered from any clinically relevant toxicities associated with any prior surgery for the treatment of glioma unless stabilized under medical management",
            "criterions": [
                {
                    "exact_snippets": "Recovered from any clinically relevant toxicities associated with any prior surgery for the treatment of glioma unless stabilized under medical management",
                    "criterion": "clinically relevant toxicities from prior glioma surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery or stabilization",
                            "expected_value": [
                                "recovered",
                                "stabilized under medical management"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Hemoglobin (Hgb) ≥ 10 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hgb) ≥ 10 g/dl",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Blood urea nitrogen (BUN) ≤ 25 mg/dl",
            "criterions": [
                {
                    "exact_snippets": "Blood urea nitrogen (BUN) ≤ 25 mg/dl",
                    "criterion": "blood urea nitrogen (BUN)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 25,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. 1st recurrence only",
            "criterions": [
                {
                    "exact_snippets": "1st recurrence only",
                    "criterion": "recurrence number",
                    "requirements": [
                        {
                            "requirement_type": "number",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "recurrence"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Alanine transaminase (ALT) ≤ 3 x normal range",
            "criterions": [
                {
                    "exact_snippets": "Alanine transaminase (ALT) ≤ 3 x normal range",
                    "criterion": "alanine transaminase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x normal range"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Clinical and/or radiographic, progressive Grade 2-3 glioma with greater than 2 cm of non-enhancing disease in one plane.",
            "criterions": [
                {
                    "exact_snippets": "Clinical and/or radiographic, progressive Grade 2-3 glioma",
                    "criterion": "glioma grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "greater than 2 cm of non-enhancing disease in one plane",
                    "criterion": "non-enhancing disease size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "plane",
                            "expected_value": "one plane"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. For females of child-bearing potential, negative serum pregnancy test at screening",
            "criterions": [
                {
                    "exact_snippets": "females of child-bearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "child-bearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative serum pregnancy test at screening",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Complete Blood Count (CBC)/differential with adequate bone marrow function as defined below within 2 weeks of enrollment:",
            "criterions": [
                {
                    "exact_snippets": "Complete Blood Count (CBC)/differential",
                    "criterion": "complete blood count (CBC)/differential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate bone marrow function as defined below",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 2 weeks of enrollment",
                    "criterion": "timing of laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Signed informed consent",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Karnofsky Performance Status (KPS) of ≥ 70",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky Performance Status (KPS) of ≥ 70",
                    "criterion": "Karnofsky Performance Status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Expected survival of ≥ 12 months",
            "criterions": [
                {
                    "exact_snippets": "Expected survival of ≥ 12 months",
                    "criterion": "expected survival",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Aspartate aminotransferase (AST) ≤ 3 x normal range",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ≤ 3 x normal range",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x normal range"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelet count ≥ 100,000 cells/mm3",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100,000 cells/mm3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "cells/mm3"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "15. Unable to undergo MRI imaging",
            "criterions": [
                {
                    "exact_snippets": "Unable to undergo MRI imaging",
                    "criterion": "ability to undergo MRI imaging",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.",
            "criterions": [
                {
                    "exact_snippets": "Major medical illnesses ... will prevent administration or completion of protocol therapy",
                    "criterion": "major medical illnesses",
                    "requirements": [
                        {
                            "requirement_type": "impact on protocol therapy",
                            "expected_value": "will prevent administration or completion"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric impairments ... will prevent administration or completion of protocol therapy",
                    "criterion": "psychiatric impairments",
                    "requirements": [
                        {
                            "requirement_type": "impact on protocol therapy",
                            "expected_value": "will prevent administration or completion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Prior therapy with mIDH1 targeted therapeutics",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy with mIDH1 targeted therapeutics",
                    "criterion": "prior therapy with mIDH1 targeted therapeutics",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating women",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Known Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition (Note: human immunodeficiency virus [HIV] testing is not required for entry into this protocol. The need to exclude patients with Acquired Immunodeficiency Syndrome (AIDS) from this protocol is necessary because treatments involved in this protocol may be significantly immunosuppressive.)",
            "criterions": [
                {
                    "exact_snippets": "Known Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition",
                    "criterion": "Acquired Immune Deficiency Syndrome (AIDS) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition_source",
                            "expected_value": "current Centers for Disease Control and Prevention (CDC) definition"
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Known hypersensitivity to any component of vorasidenib",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any component of vorasidenib",
                    "criterion": "hypersensitivity to any component of vorasidenib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Metastases detected below the tentorium or beyond the cranial vault",
            "criterions": [
                {
                    "exact_snippets": "Metastases detected below the tentorium",
                    "criterion": "metastases location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "below the tentorium"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Metastases detected ... beyond the cranial vault",
                    "criterion": "metastases location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "beyond the cranial vault"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine.",
            "criterions": [
                {
                    "exact_snippets": "Allergy or hypersensitivity to tetanus vaccine",
                    "criterion": "allergy or hypersensitivity to tetanus vaccine",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Allergy or hypersensitivity to ... any component of the tetanus vaccine",
                    "criterion": "allergy or hypersensitivity to any component of the tetanus vaccine",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Myocardial infarction within the last 6 months.",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction within the last 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Patient taking any medications that are CYP3A or CYP2C9 substrates with a narrow therapeutic index (Note: Patients should be transferred to other medications before receiving the first dose of study drug.)",
            "criterions": [
                {
                    "exact_snippets": "Patient taking any medications that are CYP3A or CYP2C9 substrates with a narrow therapeutic index",
                    "criterion": "concomitant medication (CYP3A or CYP2C9 substrate with narrow therapeutic index)",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "substrate type",
                            "expected_value": [
                                "CYP3A",
                                "CYP2C9"
                            ]
                        },
                        {
                            "requirement_type": "therapeutic index",
                            "expected_value": "narrow"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Unstable angina and/or congestive heart failure requiring hospitalization",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure requiring hospitalization",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "requiring hospitalization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Patients with known hypersensitivity to GM-CSF, yeast-derived products, or any component of Leukine®",
            "criterions": [
                {
                    "exact_snippets": "known hypersensitivity to GM-CSF",
                    "criterion": "hypersensitivity to GM-CSF",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to ... yeast-derived products",
                    "criterion": "hypersensitivity to yeast-derived products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to ... any component of Leukine®",
                    "criterion": "hypersensitivity to any component of Leukine®",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. More than 1 cm X 1 cm of enhancing disease on gadolinium contrasted MRI imaging",
            "criterions": [
                {
                    "exact_snippets": "More than 1 cm X 1 cm of enhancing disease on gadolinium contrasted MRI imaging",
                    "criterion": "enhancing disease on gadolinium contrasted MRI imaging",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "cm"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "cm"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients with active gastrointestinal disease, chronic diarrhea, previous gastric resection or lap band dysphagia, short-gut syndrome, gastroparesis, or other condition that limits the ingestion or gastrointestinal absorption of drugs administered orally (Note: Gastroesophageal reflux disease under medical treatment is allowed.)",
            "criterions": [
                {
                    "exact_snippets": "active gastrointestinal disease",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic diarrhea",
                    "criterion": "chronic diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previous gastric resection",
                    "criterion": "previous gastric resection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lap band dysphagia",
                    "criterion": "lap band dysphagia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "short-gut syndrome",
                    "criterion": "short-gut syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastroparesis",
                    "criterion": "gastroparesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other condition that limits the ingestion or gastrointestinal absorption of drugs administered orally",
                    "criterion": "condition limiting oral drug ingestion or absorption",
                    "requirements": [
                        {
                            "requirement_type": "limitation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years (e.g., carcinoma in situ of the breast, oral cavity, and cervix are all permissible)",
            "criterions": [
                {
                    "exact_snippets": "Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years",
                    "criterion": "prior invasive malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "non-melanomatous skin cancer"
                        },
                        {
                            "requirement_type": "disease free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinoma in situ of the breast, oral cavity, and cervix are all permissible",
                    "criterion": "carcinoma in situ (breast, oral cavity, cervix)",
                    "requirements": [
                        {
                            "requirement_type": "permissibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Patients with a heart-rate corrected QT interval using Fridericia's formula (QTcF) ≥ 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome)",
            "criterions": [
                {
                    "exact_snippets": "heart-rate corrected QT interval using Fridericia's formula (QTcF) ≥ 450 msec",
                    "criterion": "QTcF (heart-rate corrected QT interval using Fridericia's formula)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 450,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome)",
                    "criterion": "risk factors for QT prolongation or arrhythmic events",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "heart failure",
                    "criterion": "heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypokalemia",
                    "criterion": "hypokalemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of long QT interval syndrome",
                    "criterion": "family history of long QT interval syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Subjects with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted (Note: Patients with chronic HBV that is adequately suppressed by institutional practice will be permitted.)",
            "criterions": [
                {
                    "exact_snippets": "Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.",
                    "criterion": "active hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.",
                    "criterion": "active hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with a sustained viral response to HCV treatment ... will be permitted",
                    "criterion": "sustained viral response to HCV treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunity to prior HBV infection will be permitted",
                    "criterion": "immunity to prior HBV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with chronic HBV that is adequately suppressed by institutional practice will be permitted",
                    "criterion": "chronic HBV that is adequately suppressed",
                    "requirements": [
                        {
                            "requirement_type": "suppression status",
                            "expected_value": "adequately suppressed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Severe, active co-morbidity, defined as follows:",
            "criterions": [
                {
                    "exact_snippets": "Severe, active co-morbidity",
                    "criterion": "co-morbidity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study",
            "criterions": [
                {
                    "exact_snippets": "Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry",
                    "criterion": "treatment on other therapeutic clinical protocols",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "treated on any other therapeutic clinical protocols ... during participation in the study",
                    "criterion": "treatment on other therapeutic clinical protocols during study participation",
                    "requirements": [
                        {
                            "requirement_type": "treatment during study participation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}